View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 28, 2017

Anti-inflammatory drug minimises CV risk in Novartis’ CANTOS trial

Novartis has reported positive primary results from its Phase III CANTOS clinical trial of ACZ885 (canakinumab) quarterly injections in patients with a history of heart attacks and inflammatory atherosclerosis.

Novartis has reported positive primary results from its Phase III CANTOS clinical trial of ACZ885 (canakinumab) quarterly injections in patients with a history of heart attacks and inflammatory atherosclerosis.

ACZ885 is a selective, high-affinity, fully human monoclonal antibody being developed to inhibit the IL-1ß cytokine in the inflammatory pathway that is involved in the progression of inflammatory atherosclerosis.

The results indicated a 15% statistically significant decrease in risk of major adverse cardiovascular events (MACE), which is a composite of non-fatal heart attack, non-fatal stroke and cardiovascular (CV) death.

With 10,061 subjects enrolled over the last six years, the randomised, double-blind, placebo-controlled, event-driven CANTOS trial assessed the efficacy, safety and tolerability of subcutaneous ACZ885 and standard-of-care combination to prevent recurrent CV events.

Patients with high-sensitivity C-reactive protein (hsCRP) levels of greater than or equal to 2mg/l were recruited into the trial and administered with 50mg, 150mg or 300mg of ACZ885.

Novartis drug development global head and chief medical officer Vas Narasimhan said: "This data is a significant milestone because they show that selectively targeting inflammation with ACZ885 reduces cardiovascular risk and that ACZ885 may also be an important immuno-oncology therapy targeting IL-1ß for lung cancer.

"We look forward to submitting the CANTOS data to regulatory authorities for approval in cardiovascular and initiating additional Phase III studies in lung cancer."

"We look forward to submitting the CANTOS data to regulatory authorities for approval in cardiovascular and initiating additional Phase III studies in lung cancer."

The reduction in MACE was found to be consistent throughout the duration of the trial, including a median follow up period of 3.7 years, with the 150mg and the 300mg doses meeting the primary endpoint, while the 50mg dose was observed to be less efficacious.

An additional benefit was a decrease in the number of patients needing unplanned revascularisation for worsening chest pains.

The overall rates of adverse events (AEs), serious AEs, and discontinuations due to AEs across all ACZ885 doses were consistent with placebo, and cancer deaths were reduced by half through ACZ885.


Image: Three-dimensional (3D) illustration of the heart. Photo: courtesy of interphasesolution at FreeDigitalPhotos.net.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU